Niemann-Pick Type A PerlQuest
“Perlara’s unique drug discovery platform and business model is a perfect fit for advancing our efforts in discovering existing compounds that can be repurposed, and new novel compounds that can be optimized for treating Niemann-Pick Type A,”
— Steven Laffoon, Co-Founder and President of Wylder Nation Foundation
We got off to a running start in January, and we’re looking forward to seeing initial data in the second quarter. We’ll keep you posted about progress as we move along.
Launch your own PerlQuest
Still have questions about PerlQuests?
Follow other PerlQuests
PerlQuest updates from our Blog
The Condition: Mucolipidosis Type IV Mucolipidosis is a group of inherited lysosomal storage disorders characterized by aberrant storage and accumulation of lipid vesicles in patient cells. Mucolipidosis type IV (MLIV) is a rare genetic lysosomal storage disorder that...read more
This is the fourth post in an open science blog series about PERL101 (P101), a small molecule with big hopes. Demystifying drug discovery The default setting of biotech startups and pharma giants alike is stealth mode. At Perlara the default is set to open. As the...read more
Perlara's high throughput screen progress in Mucolipidosis IV (MLIV) flies… In this blog post, I’ll tell you about Perlara's high throughput screen progress in MLIV flies. Last year, Tom Hartl reviewed some details of MLIV disease biology and described how worms and...read more